NorthCrest Asset Manangement LLC Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

NorthCrest Asset Manangement LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,196 shares of the biopharmaceutical company's stock, valued at approximately $323,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Capital World Investors grew its stake in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after purchasing an additional 92,101 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock valued at $2,996,296,000 after buying an additional 98,303 shares during the last quarter. Capital Research Global Investors increased its holdings in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. raised its position in Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after acquiring an additional 1,245,195 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ALNY shares. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research report on Friday, March 21st. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective on the stock. Royal Bank Of Canada lifted their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. Finally, JPMorgan Chase & Co. increased their price target on Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the company an "overweight" rating in a research note on Thursday, June 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $319.58.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the sale, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded up $3.61 during trading hours on Thursday, reaching $312.32. 981,185 shares of the stock were exchanged, compared to its average volume of 932,639. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a twelve month low of $153.23 and a twelve month high of $317.54. The company has a market cap of $40.72 billion, a P/E ratio of -149.44 and a beta of 0.22. The stock has a 50 day moving average of $274.47 and a two-hundred day moving average of $260.19.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same quarter in the prior year, the business posted ($0.16) EPS. The business's revenue was up 20.2% on a year-over-year basis. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.